Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KALV stock hub

KalVista Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KALVis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.4B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KALV

In the news

Latest news · KALV

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROICn/a

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KALV market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

189

Groups with data

Currency

USD

Showing 189 of 189 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001348911
Company name	KalVista Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	483497103
Employees	275
Employees Change	5%
Employees Change Percent	1.85
Enterprise value	$1.4B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US4834971032
Last refreshed	2026-05-10
Market cap	$1.4B
Market cap category	Small-Cap
Price	$26.73
Price currency	USD
Rev Per Employee	267,698.18x
Sector	Healthcare
Sic	2834
Symbol	KALV
Website	https://www.kalvista.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-11.56%
EV Sales Forward	7.77x
EV/Sales	19.09x
FCF yield	-8.79%
P/S ratio	19.31x
PS Forward	7.86x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-225.86%
EBITDA Margin	-223.88%
Gross margin	25.73%
Gross Profit	$18.9M
Net Income	$-164.3M
Net Income Growth Years	0%
Pretax Margin	-225.27%
Profit Margin	-223.16%
Profit Per Employee	$-597,404
ROCE	-59.81

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	118.32%
Cagr3y	40.58%
Cagr5y	1.17%
EPS Growth Years	0
Revenue Growth Years	0x
Revenue Growth5 Y	80.67x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$335.4M
Cash	$300.2M
Current Assets	$320.1M
Current Liabilities	$57.4M
Debt	$284.2M
Equity	$-2.7M
Interest Coverage	-8.6
Liabilities	$338.1M
Long Term Assets	$15.2M
Long Term Liabilities	$280.7M
Net Cash	$16M
Net Cash By Market Cap	$1.13
Tangible Book Value	$-2.7M
Tangible Book Value Per Share	$-0.05
WACC	3.88

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.58
Net Working Capital	$-22.2M
Quick ratio	5.43
Working Capital	$262.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-12.33%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	118.2%
200-day SMA	15.35
3Y total return	177.86%
50-day SMA	19.68
50-day SMA vs 200-day SMA	50over200
5Y total return	5.99%
All Time High	45
All Time High Change	-40.6%
All Time High Date	2021-02-09
All Time Low	4.12
All Time Low Change	548.79%
All Time Low Date	2022-10-19
ATR	1
Beta	-0.12
Beta1y	0.43
Beta2y	0.77
Ch YTD	65.51
High	26.75
High52	26.85
High52 Date	2026-05-06
High52ch	-0.43%
Low	26.7
Low52	9.83
Low52 Date	2025-06-24
Low52ch	171.92%
Ma50ch	35.8%
Premarket Change Percent	0
Premarket Price	$26.72
Price vs 200-day SMA	74.19%
RSI	75.47
RSI Monthly	74.43
RSI Weekly	79.61
Sharpe ratio	1.35x
Sortino ratio	2.79
Total Return	-12.33%
Tr YTD	65.51
Tr1m	32.85%
Tr1w	0.3%
Tr3m	79.4%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	4
Analyst Price Target Top	$28.33
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.35
Earnings Revenue Estimate	38,861,520x
Operating Income	$-166.3M
Operating margin	-225.9
Price target	$30.8
Price Target Change	$15.23
Price Target Change Top	$5.99

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	34,586,787%
Float Percent	65.05%
Net Borrowing	208,573,500
Shares Insiders	1.7%
Shares Institutions	93.64%
Shares Out	53,167,988
Shares Qo Q	2.42%
Shares Yo Y	12.33%
Short Float	56.8%
Short Ratio	17.13
Short Shares	36.95

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-142.1M
Average Volume	6,166,140.85x
Bv Per Share	-0.05
CAPEX	$-2.6M
Ch1m	32.85
Ch1w	0.3
Ch1y	118.2
Ch3m	79.4
Ch3y	177.9
Ch5y	5.99
Ch6m	148
Change	0.04%
Change From Open	-0.04
Close	26.72
Days Gap	0.07
Depreciation Amortization	1,453,500
Dollar Volume	60,239,396.3
Earnings Date	2026-07-09
Earnings Time	bmo
EBIT	$-166.3M
EBITDA	$-164.8M
EPS	$-3.05
F Score	1
FCF	$-125M
FCF EV Yield	-8.9x
FCF Per Share	$-2.35
Financing CF	243,961,500
Fiscal Year End	December
Income Tax	$-1.5M
Investing CF	28,026,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-25
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2025-07-10
Ma150	15.98
Ma150ch	67.28%
Ma20	22.56
Ma20ch	18.46%
Net CF	146,809,500
Next Earnings Date	2026-05-22
Open	26.74
Optionable	Yes
Position In Range	60
Post Close	26.73
Postmarket Change Percent	-0.41
Postmarket Price	$26.62
Ppne	12,859,000
Pre Close	26.72
Price Date	2026-05-08
Relative Volume	0.37x
Revenue	73,617,000x
SBC By Revenue	23.26x
Share Based Comp	17,122,500
Tax By Revenue	-2.1x
Tr6m	147.96%
Us State	Massachusetts
Volume	2,253,625
Z Score	-2.56

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KALV pay a dividend?

Capital-return profile for this ticker.

Performance

KALV stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KALV?

Insider, institutional, and short-interest positioning.

Institutional ownership

+93.6%

Float: +65.1% of shares outstanding

Insider ownership

+1.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KALV momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

75.5

Above 70: short-term overbought

Price vs 200-day MA

+74.2%

50/200-day relationship not available

Beta (5Y)

-0.12

Less volatile than the market

Sharpe ratio

1.35

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KALV

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KALV stock rating?

KalVista Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KALV analysis?

The full report lives at /stocks/KALV/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KALV?

The latest report frames KALV around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KALV page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.